Actelion Ltd.: New Data On Orexin Receptor Antagonist Almorexant Shows Therapeutic Potential to Restore Normal Physiological Sleep in Patients Suffering From Insomnia
02 sept. 2007 02h21 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Sept. 2, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today the results of its proof-of-concept/dose-ranging study(1) into the effect of its first-in-class...
Actelion Announces Half Year Financial Results 2007
19 juil. 2007 01h00 HE
|
Actelion Ltd.
Total net revenue increases to CHF 626.4 million, up 43% compared
to the first six months of 2006 -- Tracleer(r) sales of CHF 559.9
million -- Cash EBIT up 59% to CHF 231.0 million -- Rapidly...
Bosentan (Tracleer) Receives EU Approval for Reduction of Number of New Digital Ulcerations in Systemic Sclerosis Patients
11 juin 2007 11h40 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, June 11, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the European Commission has granted marketing approval for Tracleer(r) for the reduction of the...
Actelion Stock Split 1:5 Effective Wednesday, 6 June 2007
31 mai 2007 01h00 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, May 31, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the one-to-five split in shares of Actelion (SWX:ATLN) will take effect on Wednesday, 6 June...
Actelion Ltd.: Annual General Meeting of Shareholders in Basel, Switzerland
04 mai 2007 06h07 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, May 4, 2007 (PRIME NEWSWIRE) -- At today's Annual General Meeting of Actelion Ltd (SWX:ATLN), shareholders approved all resolutions.
Shareholders approved the annual...
Actelion Announces First Quarter Results 2007
19 avr. 2007 01h00 HE
|
Actelion Ltd.
-- Total net revenue increases to CHF 290.4 million, up 38 percent
compared to Q1 2006
-- Tracleer(r) sales of CHF 260.4 million
-- Cash EBIT up 41% to CHF 101.3 million
-- One-time IPRD...
Actelion to Discuss First Quarter 2007 Results
13 avr. 2007 11h35 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, April 13, 2007 (PRIME NEWSWIRE) --
Dear Member of the Investment Community:
Actelion Ltd will announce the financial results of the first quarter
2007 on Thursday, 19...
Actelion Announces Bosentan -- Tracleer -- Receives Positive EU Opinion for Reduction of New Digital Ulcerations in Systemic Sclerosis Patients
26 mars 2007 08h00 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, March 26, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the...
Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
05 mars 2007 01h00 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, March 5, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today the initial results from the double-blind, placebo-controlled, multicenter study BENEFiT (Bosentan...
Actelion Announces Full Year 2006 Financial Results
22 févr. 2007 01h00 HE
|
Actelion Ltd.
-- Total net revenue up 43% to CHF 945.7 million
-- Tracleer(r) sales up 42% to CHF 898.7 million
-- Operating income up 76% to CHF 268.2 million
-- Net income up 92% to CHF 241.1 million
...